- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Business Brief
IBA teams with maker of novel PET agent
IBA teams with maker of novel PET agent
Ion Beam Applications and NeuroSurvival Technologies will work together to distribute, as well as optimize the radiochemistry of, NST's molecular imaging agent for apoptosis, the genetically controlled process of cell death associated with many diseases, including cancer. The agent, Aposense, will be distributed to sites participating in multicenter clinical trials to document whether the PET radiotracer incorporating fluorine-18 selectively targets and accumulates within cells undergoing apoptosis. IBA Molecular, a business unit of IBA, provides PET radiopharmaceuticals through a global network of radiopharmacies using 37 cyclotron-equipped manufacturing sites.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
